Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BTAI BioXcel Therapeutics	$5.24 +1.6%	$2.76	$1.17 ▼ $13.36	$76.28M	0.05	5.07 million shs	6.22 million shs
CSCI COSCIENS Biopharma	$3.00 +2.4%	$3.55	$1.96 ▼ $4.61	$9.45M	0.91	13,943 shs	8,904 shs
KLTO Klotho Neurosciences	$0.74 -2.3%	$1.11	$0.11 ▼ $3.91	$45.21M	10.9	17.10 million shs	963,440 shs
RNXT RenovoRx	$0.93 +3.7%	$1.23	$0.75 ▼ $1.69	$34.13M	1.26	157,223 shs	114,302 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BTAI BioXcel Therapeutics	+3.61%	-8.99%	+185.08%	+271.22%	-52.50%
CSCI COSCIENS Biopharma	-10.94%	+1.38%	-25.56%	-15.29%	+292,999,900.00%
KLTO Klotho Neurosciences	+0.71%	-4.10%	-38.69%	+259.10%	+75,409,900.00%
RNXT RenovoRx	-4.46%	-4.43%	-29.26%	-27.55%	-11.03%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BTAI BioXcel Therapeutics	4.5485 of 5 stars	3.4	5.0	0.0	4.5	3.0	1.7	0.6
CSCI COSCIENS Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KLTO Klotho Neurosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RNXT RenovoRx	2.8594 of 5 stars	3.5	5.0	0.0	0.0	2.1	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BTAI BioXcel Therapeutics	2.80	Moderate Buy	$39.75	658.59% Upside
CSCI COSCIENS Biopharma	0.00	N/A	N/A	N/A
KLTO Klotho Neurosciences	0.00	N/A	N/A	N/A
RNXT RenovoRx	3.00	Buy	$7.25	678.48% Upside

Current Analyst Ratings Breakdown

Latest CSCI, KLTO, RNXT, and BTAI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/15/2025	BTAI BioXcel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00
6/5/2025	RNXT RenovoRx	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $11.50

(Data available from 8/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BTAI BioXcel Therapeutics	$868K	87.88	N/A	N/A	($30.01) per share	-0.17
CSCI COSCIENS Biopharma	$9.59M	0.99	N/A	N/A	$3.49 per share	0.86
KLTO Klotho Neurosciences	N/A	N/A	N/A	N/A	$0.04 per share	N/A
RNXT RenovoRx	$40K	853.30	N/A	N/A	$0.19 per share	4.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BTAI BioXcel Therapeutics	-$59.60M	-$12.64	N/A	N/A	N/A	-5,869.82%	N/A	-134.45%	11/13/2025 (Estimated)
CSCI COSCIENS Biopharma	-$15.31M	-$6.01	N/A	∞	N/A	-199.55%	-149.49%	-54.80%	11/11/2025 (Estimated)
KLTO Klotho Neurosciences	-$6.15M	-$0.45	N/A	∞	N/A	N/A	-325.88%	-242.15%	N/A
RNXT RenovoRx	-$8.81M	-$0.38	N/A	N/A	N/A	N/A	-120.68%	-89.23%	11/12/2025 (Estimated)

Latest CSCI, KLTO, RNXT, and BTAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2025	Q2 2025	KLTO Klotho Neurosciences	N/A	-$0.12	N/A	-$0.12	N/A	N/A
8/14/2025	Q2 2025	CSCI COSCIENS Biopharma	N/A	-$0.85	N/A	-$0.85	N/A	$2.75 million
8/14/2025	Q2 2025	RNXT RenovoRx	-$0.08	-$0.08	N/A	-$0.08	$0.25 million	$0.42 million
8/12/2025	Q2 2025	BTAI BioXcel Therapeutics	-$2.30	-$2.45	-$0.15	-$2.45	$0.21 million	$0.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BTAI BioXcel Therapeutics	N/A	N/A	N/A	N/A	N/A
CSCI COSCIENS Biopharma	N/A	N/A	N/A	N/A	N/A
KLTO Klotho Neurosciences	N/A	N/A	N/A	N/A	N/A
RNXT RenovoRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BTAI BioXcel Therapeutics	N/A	0.76	0.74
CSCI COSCIENS Biopharma	N/A	2.98	2.65
KLTO Klotho Neurosciences	N/A	135.73	135.73
RNXT RenovoRx	N/A	8.61	8.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BTAI BioXcel Therapeutics	30.68%
CSCI COSCIENS Biopharma	0.73%
KLTO Klotho Neurosciences	20.07%
RNXT RenovoRx	3.10%

Insider Ownership

Company	Insider Ownership
BTAI BioXcel Therapeutics	21.20%
CSCI COSCIENS Biopharma	0.10%
KLTO Klotho Neurosciences	26.70%
RNXT RenovoRx	9.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BTAI BioXcel Therapeutics	90	14.56 million	12.62 million	Optionable
CSCI COSCIENS Biopharma	20	3.15 million	3.14 million	N/A
KLTO Klotho Neurosciences	N/A	61.37 million	44.99 million	N/A
RNXT RenovoRx	6	36.65 million	33.30 million	Not Optionable

CSCI, KLTO, RNXT, and BTAI Headlines

Recent News About These Companies

RenovoRx (NASDAQ:RNXT) Upgraded by Wall Street Zen to Hold Rating

August 23 at 2:09 AM | americanbankingnews.com

Discovering the Next Wave of Biotech Innovation (MDCX, RNXT, JSPR, LSB)

August 22, 2025 | theglobeandmail.com

FY2025 EPS Estimates for RenovoRx Increased by HC Wainwright

August 22, 2025 | americanbankingnews.com

FY2027 EPS Estimates for RenovoRx Cut by HC Wainwright

August 21, 2025 | americanbankingnews.com

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 27th Annual Global Investment Conference in New York City, September 8-10, 2025

August 20, 2025 | finance.yahoo.com

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025

August 20, 2025 | businesswire.com

RenovoRx, Inc. (NASDAQ:RNXT) Q2 2025 Earnings Call Transcript

August 19, 2025 | msn.com

RenovoRx Revenue Jumps 28 Percent in Q2

August 14, 2025 | theglobeandmail.com

RenovoRx Reports Strong Q2 2025 Revenue Growth

August 14, 2025 | msn.com

RenovoRx, Inc. (RNXT) Reports Q2 Loss, Tops Revenue Estimates

August 14, 2025 | zacks.com

RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

August 14, 2025 | businesswire.com

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

August 6, 2025 | globenewswire.com

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

July 28, 2025 | finance.yahoo.com

RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

July 14, 2025 | businesswire.com

Insider Buying: RenovoRx, Inc. (NASDAQ:RNXT) Insider Buys 21,000 Shares of Stock

June 10, 2025 | insidertrades.com

RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results

June 6, 2025 | finance.yahoo.com

Ascendiant Capital relève l’objectif de cours de l’action RenovoRx à 11,50€

June 5, 2025 | fr.investing.com

Earnings call transcript: RenovoRx Q1 2025 revenue exceeds expectations

May 17, 2025 | investing.com

RenovoRx, Inc. (NASDAQ:RNXT) Q1 2025 Earnings Call Transcript

May 17, 2025 | msn.com

RenovoRx Inc (RNXT) Q1 2025 Earnings Call Highlights: Promising Revenue Growth and Clinical ...

May 16, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSCI, KLTO, RNXT, and BTAI Company Descriptions

BioXcel Therapeutics NASDAQ:BTAI

$5.24 +0.08 (+1.55%)

Closing price 04:00 PM Eastern

Extended Trading

$6.14 +0.90 (+17.18%)

As of 05:01 PM Eastern

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

COSCIENS Biopharma NASDAQ:CSCI

$3.00 +0.07 (+2.39%)

Closing price 03:53 PM Eastern

Extended Trading

$3.02 +0.02 (+0.50%)

As of 04:19 PM Eastern

COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Klotho Neurosciences NASDAQ:KLTO

$0.74 -0.02 (-2.32%)

As of 04:00 PM Eastern

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

RenovoRx NASDAQ:RNXT

$0.93 +0.03 (+3.66%)

Closing price 03:55 PM Eastern

Extended Trading

$0.93 0.00 (-0.35%)

As of 04:40 PM Eastern

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time